R D Solution Consultant

RAMKRISHNA (RAMU) SADHUKHAN, Ph.D.

AbbVie Bioresearch Center

Division of Biotherapeutics & Genetic Medicine

Worcester, MA

978-***-**** (Cell)

Email: ****.*********@*****.***

SUMMARY:

Accomplished scientific leader with extensive experience in therapeutic protein, cell, and antibody engineering, mRNA modification and formulation, and small molecule drug discovery. Proven track record in leading multidisciplinary teams within matrixed environments at AbbVie Bioresearch Center, Vertex, and Pfizer.

Passionate about advancing biologics innovation, I specialize in antibody discovery, bispecific antibody design, targeted therapeutic fusion protein design, mRNA modification, lipid nanoparticle (LNP) formulation, mRNA-LNP targeted delivery for gene therapy, and strategic collaborations bridging industry and academia. With expertise in due diligence for in-licensing monoclonal antibodies, bispecific antibodies, and mRNA modalities, I have successfully guided multiple biologics, mRNA-LNP, and small molecule programs from early-stage discovery to late-stage candidate selection.

I thrive in leading high-performing technical teams, fostering a culture of scientific excellence and innovation that drives impactful therapeutic advancements. Always open to meaningful collaborations that shape the future of biologics and mRNA therapeutics.

Expert in due diligence of biologics assets, including monoclonal antibodies, multispecifics antibodies, and cell therapeutics, guiding strategic decision-making for acquisitions, collaboration with CROs.

PROFESSIONAL EXPERIENCE:

Senior Principal Research Scientist Head of mRNA-Based Therapeutics Platform

AbbVie Bioresearch Center Genetic Medicine, Division of Biotherapeutics & Genetic Medicine (2023–Present)

Driving innovation in mRNA therapeutics and lipid nanoparticle (LNP) technology, I lead the development of a cutting-edge gene delivery platform that is shaping the future of genetic medicine. With a strategic focus on RNA modification, formulation, and therapeutic optimization for targeted delivery, I spearhead the advancement of novel modalities to enhance drug-like properties and clinical efficacy.

Key Leadership Accomplishments:

Built the LNP-based gene delivery platform, unlocking next-generation applications in genetic medicine.

Recruited world-class subject matter experts (SMEs) in mRNA engineering and LNP formulation

Developed novel RNA modifications, conjugation, optimizing stability, translation efficiency, and therapeutic potency.

Established an industry-leading mRNA-LNP production and characterization framework, ensuring analytical rigor and manufacturing excellence.

Led strategic due diligence efforts, evaluating emerging genetic medicine therapeutics and guiding investment decisions.

Forged impactful industry and academic collaborations, accelerating innovation through external partnerships.

Co-led an mRNA therapeutics program, shaping scientific direction and driving operational success.

Making strategies on collaboration with CROs.

Implemented mRNA, LNP digital registration and request system in collaboration with IT.

Senior Principal Research Scientist, Head of Therapeutic Protein Engineering Group

Cell and Protein Sciences, Division of Biotherapeutics, AbbVie Bioresearch Center, Worcester, MA

(2021 – 2023)

Principal Research Scientist, Cell and Therapeutic Protein Engineering Group

Cell and Protein Sciences, Division of Biotherapeutics, AbbVie Bioresearch Center, Worcester, MA

(2014 – 2020)

Senior Group Leader, Protein Engineering & Expression Group

Global Protein Sciences, Division of Biologics, AbbVie Bioresearch Center, Worcester, MA

(2008 – 2014)

Key Leadership Accomplishments

Spearheaded complex bispecific and monoclonal antibody (mAb) programs in partnership with the Immunology Therapeutic Area, driving innovation in therapeutic antibody development.

Co-led/key contributor of 5 biologics programs from discovery to candidate selection/IND filling.

Led and mentored a collaborative team of 10 scientists (5 PhDs, 5 MS/BS), ensuring the successful delivery of high-quality protein reagents and cell lines for biologics discovery programs, with expertise in advanced sequence analysis.

Directed the protein engineering & expression group, providing critical support in sequence analysis, bispecific and fusion proteins design, and cell line engineering for early discovery to late discovery programs.

Established a state-of-the-art cell engineering platform, significantly advancing biologics development capabilities.

Developed a mammalian scale-up laboratory, optimizing production efficiency and scalability for mAbs and multi-specific antibodies.

Led due diligence for multiple biologics assets, including monoclonal antibodies, multispecifics, and cell therapeutics, guiding strategic decision-making for acquisitions.

Led Biologics (antibody, bispecific, fusion protein) registration and request systems.

Scientific Contributions

Co-led a high-profile bispecific immunology program, contributing to transformative research in the field.

Co-led a high-profile mAb program spanning multiple indications, fostering critical advancements.

Established strategic collaborations with multiple therapeutic leadership teams, ensuring seamless program transitions within the development pipeline.

Key contributor to ABT-308 (anti-IL13), ABBV-022 (anti-IL-TNF/IL-17 DVD-Ig).

Core team member of ABT-981 (anti-IL-1ab-DVD-Ig, in Phase III), ABBV-642 (anti-VEGF/PDGF DVD-Ig).

Co-led ABBV-022 (Bifunctional fusion protein, VH/VL of Tenascin C attached to IL-22), a targeted fusion proteins.

Mapped the epitope of ABT-874 antibody and five anti-IL-12 antibodies, leading to patented discoveries.

Developed a Cyno database, enhancing the understanding and management of biologic therapeutics.

Implemented two novel mammalian expression systems, CHO-EBNA transient and Expi 293, expanding production methodologies.

Major contributor to the Jak2_Tyk2 structural biology work, integral to the development of Rinvoq, a multi-billion-dollar drug.

Performed due diligence of multiple biologics assets (Monoclonal mAb, Multispecific, cell therapeutic) in guiding strategic decision-making for acquisition.

Selected CROs for antigen, antibody, and cell line development.

Senior Scientist II, Department of Molecular and Cellular Biology

Abbott Labs, Abbott Bioresearch Center, Worcester, MA

(2003 – 2008)

Key Leadership Accomplishments:

Led a team of three scientists (MS-level) specializing in cloning, protein engineering, expression, and stable cell line generation for immunization and cell-based assay development.

Established a high throughput cloning and expression platform, optimizing efficiency in biologics research and discovery.

Fostered cross-functional collaborations with key teams, including antigen purification, assay development, hybridoma, and structural biology, ensuring seamless integration across scientific disciplines.

Scientific Contributions & Innovation

Developed a platform approach for generating diverse cell lines (HEK293, BAF3, CHO) to support immunization and assay development.

Designed a novel method for natural IL-13 production from PBMC, successfully delivering critical quantities for the ABT-308 (anti-IL-13) program.

Pioneered the expression of dimeric and trimeric proteins as single-chain constructs, enhancing protein engineering capabilities.

Established single-chain cynomolgus IL-23 for IL-12 (ABT-874) and IL-12 backup (ABT-147) production, contributing to biologics development pipelines.

Generated essential protein reagents for multiple biologics programs, supporting diverse therapeutic initiatives.

Mapped the epitope of ABT-874 and five additional anti-IL-12 backup antibodies, leading to patentable discoveries.

Conducted cross-reactivity studies (via immunoprecipitation) on anti-IL-12 antibodies and EBI-3_IL-27, advancing immunology research.

Led and supervised the biochemistry division of multiple small molecule projects, including MK2, Tyk2, Jak3, contributing to structure-based drug design strategies.

Implemented a high-throughput cloning, mutagenesis, and expression screening platform, accelerating molecular biology workflows.

Designed and delivered highly customized protein constructs (50–100 per project) for target kinases to support high-throughput protein crystallography and structure-based drug design, including 50+ constructs for MK2 and 100+ constructs for Jak3.

Developed and implemented a Rapid Expression System (InsectDirect) for high-throughput protein expression screening.

Served as target champion and co-project leader for two biologics programs, leading research strategy and execution.

Investigator, Protein Biochemistry, Vertex Pharmaceuticals, Cambridge, MA

(2000 – 2003)

Scientific Achievements of the group (includes my own contributions):

Worked on HT expression and purification of Protease and Kinase gene families in prokaryotic and eukaryotic expression systems

Successfully designed the constructs, expressed, isolated and purified 60 Proteases and 6 Kinases in two different expression systems (bacteria and insect cell).

Scaled up the large-scale production and purification of Proteases and Kinases for HTS and structural studies

Designed the constructions and provided proteins for 3 novel X-ray structures

Successfully implemented robotic/automation technology for HT protein expression and purification.

Proposed New therapeutic targets, one of which was approved as project.

Scientific Leadership:

Recruited, directed, and led 1 MS and 1BS scientist.

Post-doctoral Scientist, Protein Science, Pfizer, Kalamazoo, MI

(1999 – 2000)

Cloned human procaspase-9 from human heart cDNA library.

Successfully expressed recombinant procaspase-9 in E. coli.

Standardized the folding refolding method and produced large quantities of active protein for HTS and crystallographic studies.

Characterized the E. coli expressed recombinant caspase 9.

Showed the caspase-9 activity toward Glu-X bonds

Research Associate, Dept of Molecular Cardiology, Cleveland Clinic Foundation, OH

(1997-1999)

Worked on ACE89 mouse mammary epithelial cells, permanently transfected with rabbit testicular angiotensin-converting enzyme (ACE) cells to establish a genetic system to directly identify the cellular components involved in the cleavage-secretion of ACE.

Postdoctoral Research Fellow, Dept. of Molecular Cardiology, Cleveland Clinic Foundation, OH

(1993-1997)

Identified the structural determinants of ACE which regulates its cleavage-secretion from the cell surface.

Determined the role of glycosylation on cleavage-secretion of ACE.

Successfully expressed mammalian ACE in the methylotropic yeast Pichia pastoris.

Senior Research Fellow, Dept of Microbiology, Bose Institute, Calcutta, India

(1990 – 1993)

Purified and characterized a-amylase produced by a thermophilic strain Myceliophthora thermophila D-14

Studied its application toward practical saccharification and production of ethanol.

Research Fellow, Dept of Microbiology, Bose Institute, Calcutta, India

Studied the production and catabolic repression of a-amylase of Myceliophthora thermophila D-14 (a thermophilic fugus)

EDUCATION:

Ph.D., Biochemistry University of Calcutta, Calcutta, India

M.S., Biochemistry University of Calcutta, Calcutta, India

B.S., Chemistry (Major) University of Calcutta, Calcutta, India

Physics & Math (Minor)

ACADEMIC AND PROFESSIONAL AWARDS AND HONORS:

2017 – 2023 6 VP Awards (AbbVie)

Site Leader Award

Leadership award for exceptional collaboration.

ABBV-022 team and Targeted Cytokine Platform - To boldly go where no one has gone before!" from site head

“Raising the Roof” award for IL-22 Fusion protein platform from Immunology VP

“Planting Seeds” award for external collaboration from Immunology VP

VP Global Biologics "Monkey Business Award" from site head

1995 – 1997 American Heart Association Fellowship

The Fellowship application ranked in the top 5 percentile in the North Eastern Ohio Affiliate

1989 - 1993 Sr. Research Fellow, Bose Institute, Calcutta, India

1987 - 1989 Jr. Research Fellow, Bose Institute, Calcutta, India

1981 – 1984 Merit Scholarship, Govt. of India

Academically Judged Traineeship Awards and Training:

1990 Bioprocess Technology of Enzymes & Fuels, Madurai Kamraj University, India

1991 Mathematical Models in Biology, Calcutta Mathematical Society, India

2004 Successfully completed the 2004 American Association of Immunologists “Introductory Course in Immunology Part I and II”

PATENT:

INTERLEUKIN-22 (IL-22) FUSION PROTEINS AND USES THEREOF

(WBD Docket No. 1030171520US.P1 (0622.5), AbbVie Docket No. ABV12542USL1)

Anti-IL-12/IL-23 Antibodies and Uses Thereof Docket No. 117***-*****

PUBLICATIONS:

1.Zhi Su, Samrawit Aforki, Zachary K. Goldsmith, Sheila Cummings, Kathleen M. Smith, Xin Chen, Stacy H. Ryu, Anastasia E. Marinopoulos, Joseph B. Wetter, Samuel Karsen, Nancy Crosbie,

Laura Wasserman, Elizabeth Asque, Gricelda Simler, Stephanie E. Paulsboe, Samantha Ciura, Danyl Butt, Heath A. McDonald, Ramkrishna Sadhukhan, Viktor Todorovic, Victoria E. Scott, Jacqueline Loud (2025) Cellular, molecular, and pharmacological characterization of a house dust mite (HDM)-induced murine models of dermatitis -in preparation

2.Ana Ramon-Vazquez, Angieszka Skowyra, Tadhg Crowley, Janaki Velmurugan, Ciaran Lee, Andrew J. Lindsay, Jerzy Woznicki, Panagiota Stamou, Amanda J. Lohan, Werner C. Albrich, Liam O’Mahony, Silvia Melgar, Xiaohong Cao, Mike Macoritto, Ramkrishna Sadhukhan, Marc C Lavesque, Bradford L. McRae, Melissa Matzelle, Ken Nally (2025) IL-32 drives inflammatory responses in IFN-g primed human macrophages via a Myddosome-dependent pathway and is elevated in COVID-19 (in preparation)

3.Ramkrishna Sadhukhan et al Sustained Chondroprotective Effect of Targeted IGF-1 Fusion Protein in Rat Model of Osteoarthritis. In preparation (to be submitted in Nature Biotech)

4.Radhika Goenka, Zhenghai Xu, Josue Samayoa, David Banach, Christine Beam, Sahana Bose, Gerri Dooner, Charles M. Forsyth, Xiaoqing Lu, Limary Medina, Ramkrishna Sadhukhan, Bernhard Sielaff, Silvino Sousa, Qingfeng Tao, Debra Touw, Fei Wu, Gillian Kingsbury and Yoshiko Akamatsu (2020) CTLA4-Ig Based Bifunctional Co-Stimulation Inhibitor blocks CD28 and ICOS Signaling to Prevent T cell Priming and Effector function. The Journal of Immunology doi:10.4049/jimmunol.2001100

5.Ramkrishna Sadhukhan, Nathan Brown, David Ouellette, David Banach, Dana Filoti, David Winarta, Reema Raghavendra, Silvino Sousa Anhdao Darcy, Leslie Alessandri, Alexander Ivanov, Sahana Bose, Lucia Eaton, Gregory Preston, Jeremy Freeman, and Ivan Correia (2018). Engineering Elastic Properties into an Anti-TNF-a Monoclonal Antibody. Cogent Biology 4: 1469387

6.Li Zhou, Viktor Todorovic, Steve Kakavas, Bernhard Sielaff, Limary Medina, Leyu Wang, Ramkrishna Sadhukhan, Henning Stockmann, Paul L. Richardson, Enrico DiGiammarino, Chaohong Sun and Victoria Scott (2017) Quantitative ligand and receptor binding studies reveal the mechanism of interleukin-36 (IL-36) pathway activation. Journal of Biological Chemistry November 27, 2017 Manuscript M117.805739

7.Henning Stockmann, Viktor Todorovic, Paul L. Richardson, Violeta Marin, Victoria Scott, Clare Gerstein, Marc Lake, Leyu Wang, Ramkrishna Sadhukhan, Anil Vasudevan (2017). Cell-surface receptor-ligand interaction analysis with homogenous time-resolved FRET and metabolic glycan engineering: application to transmembrane and GPI-anchored receptors. JACS 139 (46-168**-*****.

8.Kun Ding, Lucia Eaton, Diana Bowley, Matthew Rieser, Qing Chang, Maria C. Harris, Anca Clabbers, Feng Dong, Jikui Shen, Sean F. Hackett, Debra S. Touw, Jacqueline Bixby, Suju Zhong, Lorenzo Benatuil, Sahana Bose, Christine, Grinnell, Gregory M. Preston, Ramesh Iyer, Ramkrishna Sadhukhan, Susan Marchie, Gary Overmeyer, Tariq Ghayur, Deborah A. van Riet, Shibo Tang, Peter A. Campochario & Jijie Gu (2017). Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGFBB and is designed for the treatment of exudative age-related macular degeneration. Mabs 9, 269-284.

9.Maria A. Argiriadi, Eric R. Goedken, Dave Banach, David Borhani, Andrew Burchat, Doug Marcotte, Gary Overmeyer, Valerie Pivorunas, Ramkrishna Sadhukhan, Silvino Sousa, Nigel St. John Moore, Medha Tomlinson, Jeff Voss, Lu Wang, Neil Wishart, Kevin Woller, Robert V. Talanian (2012). Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor. BMC Structural Biology. 12 1-13

10.Maria A. Argiriadi, Anna M. Ericsson, Christopher Harris, David Banach, David W. Borhani, David J. Calderwood, Megan Demers, Jennifer DiMauro, Ricard D W. Dixon, Jennifer hardman, Silvia Kwak, Biqin Li, John A. Manovich, Douglas Marcotte, Kelly D. Mullen, Baofu Ni, M. Pietras, Ramkrishna Sadhukhan, Silvino Sousa, Medha J. Tomlinson, Lu wang, Tao Xiang, Robert V. Talanian (2010), 2,4 Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode. Bioorganic & Medicinal Chemistry Letters. 20 330-333

11.Maria A. Argiriadi, Silvino Sousa, David Banach, Douglas Marcotte, Tao Xiang, Medha J. Tomlinson, Megan Demers, Christopher Harris, Silvia Kwak, Jennifer Hardman, Margaret Pietras, Lisa Quinn, Jennifer DiMauro, Baofu Ni, John Mankovich, David W. Borhani, Robert V. Talanian, and Ramkrishna Sadhukhan (2009) Rational mutagenesis to support structure-based drug design: MK2 as a case studies. BMC Structural Biology 9 1-13

12.Miller, R, Sadhukhan R, and Wu C (2008) Development of an in vitro potency bioassay for therapeutic IL-13 antagonists: The A-549 cell bioassay. Journal of Immunological Methods 334 134-141

13.Sadhukhan, R., Leone, J. W., Lull, J., Wang, Z., Kletzien, R. F., Henriksen, R. L., and Tomasselli, A.G. (2006). Recombinant Human Caspase-9, a Unique Caspase with Activity Towards Glu-X Bonds. Protein Expression and Purification. 46: 299-308.

14.Sadhukhan, R., Santhamma. K.R., Kinter, M., Chattpadhyay, S., McCue, and Sen, I. (2004). Role of Tyrosine Phosphorylation in the Regulation of Cleavage Secretion of Angiotensin-converting Enzyme. Journal of Biological Chemistry. 279: 402**-*****.

15.Sadhukhan, R, Santhamma, K. R., Reddy, P., Peschon, J. J., Black, R. A., and Sen, I. (1999). Unaltered Cleavage-Secretion of Angiotensin-converting Enzyme in Tumor Necrosis Factor a-Converting Enzyme Deficient Mice. Journal of Biological Chemistry. 274: 105**-*****.

16.Sadhukhan, R., Sen, G. C., Ramchandran, R., and Sen, I. (1998). Distal Ectodomain of Angiotensin-converting Enzyme Regulates its Cleavage-Secretion from Cell Surface. Proceedings of National Academy of Science. 95: 138 - 143.

17.Sadhukhan, R., Sen, G. C., and Sen, I. (1996). Synthesis and Cleavage-Secretion of Enzymatically Active Rabbit Angiotensin-converting Enzyme in Pichia pastoris. Journal of Biological Chemistry 271:18310 - 18313.

18.Sadhukhan, R., and Sen, I. (1996). Different Glycosylation Requirements for the Synthesis of Enzymatically Active Angiotensin-converting Enzyme in Mammalian Cells and Yeasts. Journal of Biological Chemistry. 271: 6429 - 6434.

19.Manna, S., Sinha, A., Sadhukhan, R., and Chakrabarty, S. L. (1995). Purification Characterization and Antitumor Activity of L-Asparaginase Isolated from Pseudomonas stutzeri MB-405. Current Microbiology. 30: 291-298.

20.Sadhukhan, R., Roy, S. K., and Chakrabarty, S. L. (1993). Immobilization of µ-Amylase from Myceliophthora thermophila D-14 (ATTC 48104). Enzyme and Microbial Technology. 15: 801-804.

21.Sengupta, D. K., and Sadhukhan, R. (1992). Byproduct Utilization and Optimization of Different External Factors in Ethanol Fermentation of Sugar Cane Molass1es in Batch Process. Indian Chemical Engineers. 34: 85-90.

22.Sadhukhan, R., Roy, S. K., Raha, S. K., Manna, S., and Chakraborty, S. L. (1992). Induction and Regulation of µ-Amylase Synthesis in a Cellulolytic Thermophilic Fungus Myceliophthora thermophila D-14 (ATCC 48104). Indian Journal of Experimental Biology. 30: 482-486.

23.Roy, S.K., Sadhukhan, R., Raha, S. K., and Chakrabarty, S. L. (1991). Enzymatic Hydrolysis of Different Pretreated Cellulosic Wastes by the Cellulase Complex of Myceliophthora thermophila D-14 to Produce Ethanol. Fuel. 10: 757-760.

24.Roy, S. K., Raha, S. K., Sadhukhan, R., and Chakrabarty, S. L. (1991). Purification and Characterization of Extracellular b- Glucosidase from Myceliophthora thermophila D-14 (ATCC 48104). World Journal of Microbiology and Biotechnology. 7: 613-618.

25.Sadhukhan, R., Manna, S., Roy, S. K., and Chakrabarty, S.L. (1990). Thermostable Amylolytic Enzymes from a Cellulolytic Fungus Myceliophthora thermophila D-14 (ATCC). Applied Microbiology and Biotechnology. 33: 692-696.

ABSTRACTS PRESENTED:

Cutler, L., Pietras, M., White, M. K., Lu, X., DiMauro, J., Mankovich, J., and Sadhukhan, R. (2006). Expression, Purification, and Characterization of CD19: a Potential Therapeutic Target for Autoimmune Diseases. PEGS: Protein Engineering Summit. Boston, MA, April 24-28.

Sadhukhan, R., Dawson, M. N., Austen, D. A., Singamsatti, S., Aldape, R., Parson, J. D., Chambers, S. P. (2003). Expression, Purification and Characterization of Angiotensin-converting Enzyme-2 (ACE2) in Baculovirus-infected Insect Cells. “17th Symposium of The Protein Society” Boston, MA, July 26-30

Sadhukhan, R., Santhamma, K. R., Reddy, P., Peschon, J. J., Black, R. A., and Sen, I. (1998). Unaltered Cleavage-Secretion of Angiotensin converting Enzyme in Tumor Necrosis Factor Converting Enzyme Deficient mice. Mechanisms of Tumor Growth & Invasion Mediated by Proteolysis. San Francisco, USA, November 5 – 6.

Sadhukhan, R., Sen, G. C., and Sen, I. (1998). The Distal Ectodomain of Angiotensin-converting Enzyme Regulates its Cleavage-secretion. XVI World Congress of the International Society for Heart Research, Cardiovascular Biology and Medicine into the 21st Century. Rhodes, Greece, May 27-31.

Sen, I., and Sadhukhan, R. (1997). Structural Requirements for the Ectodomain Cleavage of Rabbit Angiotensin Converting Enzyme. Keystone Symposia on Processing of Peptide Hormones, Neurotransmitters, Growth Factors and Viral Proteins (X2). Taos, New Mexico, USA, March 3-9.

Sadhukhan, R., Sen, G. C., and Sen, I. (1996). Synthesis and Cleavage-Secretion of Enzymatically Active Rabbit Angiotensin Converting Enzyme in Pichia pastoris. 6th International Congress on Cell Biology & 36th American Society for Cell Biology Annual Meeting, San Francisco, California, USA, March 3-9.

Sadhukhan, R., and Sen, I. (1996). Different Glycosylation Requirements for the Synthesis and Proteolytic Processing of Enzymatically Active Angiotensin-converting Enzyme in Mammalian Cells and Yeasts. Keystone Symposia on Molecular and Cellular Biology, Keystone, Colorado, USA, March 25-31.

Sadhukhan, R., and Chakrabarty, S. L. (1989). Amylase from a Cellulolytic Fungus Myceliophthora thermophila D-14 (ATCC 48104). 76th Session of the Indian Science Congress Association. Madurai Kamraj University, Madurai, India, June 7-12.

Sadhukhan, R., and Chakrabarty, S. L. (1989). Production of Amylolytic Enzymes from Myceliophthora thermophila D-14. 58th Annual Meeting of the Society of Biological Chemists (India), Izatnagar, India. October 16-18.

INVITED SPEAKER:

1.Designing Better Therapeutics by Understanding the Complexity of the Target Ortholog in Nonhuman Primates. Pep Talk, January 2020

2.Challenges in Generating Functional Antibodies Against Integral Membrane Proteins. Pep Talk, San Diego, January 2016

3.Antibodies Against Membrane Proteins-Finding Path to Success Through Case Studies. Discovery on Target, Boston, October 8-10, 2014.

4.Different Expression Systems and their Importance for Biologics Drug Discovery Research. Proteins & Biopharma Asia Congress, September 10-11, 2012, Singapore

5.Protein Production for Biologics Drug Discovery. Bose Institute, Kolkata, India, February 23, 2012.

6.Challenges in scale-up of a heterodimeric cytokine IL-23. Global Protein Summit. Lord’s Cricket Ground, London, June 6-7, 2007

7.Development of high-throughput technology of protein expression to support structure-based drug design: An inflammatory Ser/Thr kinase case study. PEP TALK. Protein Information Week. San Diego, CA. January 10-13, 2006.

COMPANY REPORTS/ABSTRACTS:

Author of more than 50 reports, poster abstracts from Abbott/AbbVie, Pharmacia/Pfizer, Vertex.

ADDITIONAL QUALIFICATIONS:

People-oriented, results oriented

Well organized, hard working, and cooperative

Strongly self-motivated, and assume responsibility easily

Like to work in a team-oriented environment

Contact this candidate